Vol. 4 No. 6 (2024)
Reimbursement Reviews

Trifluridine-Tipiracil (Lonsurf)

Published June 13, 2024

Key Messages

  • CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
  • The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec.
  • This review assesses trifluridine-tipiracil (Lonsurf), 15 mg trifluridine/6.14 mg tipiracil (as tipiracil hydrochloride) and 20 mg trifluridine/8.19 mg tipiracil (as tipiracil hydrochloride), oral tablets.
  • Indication : For the treatment of adult patients with metastatic colorectal cancer who have been previously treated with, or are not candidates for, available therapies, including fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapies, anti-VEGF biological agents, and, if RAS wild-type, anti-EGFR agents.